FDA Approved: BYOOVIZ — Supplemental Application (BIOGEN INC.)

View source ↗

Summary

FDA approved a supplemental application for BYOOVIZ (ranibizumab-nuna) from Biogen Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Diabetic Macular Edema
• Macular Edema Following Retinal Vein Occlusion
• Myopic Choroidal Neovascularization

Drugs mentioned

• BYOOVIZ (ranibizumab-nuna)

Snippet

SUPPL AP for BYOOVIZ (RANIBIZUMAB-NUNA)